Genetic Signatures Ltd. products

In the United States (US), gastrointestinal (GI) protozoan parasites are a significant healthcare burden, with more than 350 million cases of acute GI infections annually. Globally, protozoan infections are the leading cause of mortality of children under five years old.^1,2 Hence, the importance of rapid and accurate diagnosis and treatment is essential for decreasing the significant burden of GI infections. The Center for Disease Control and Prevention (CDC) recorded a steady increase in reported GI protozoan outbreaks in the US over the past 12 years until 2020 (refer to the chart below). At this point, COVID-19 restrictions significantly decreased outbreaks due to reduced mobility, and decreased local and international travel. However, now that restrictions have lifted, reported weekly parasite infections from the National Notifiable Diseases Surveillance System (NNDS) indicate a lift in reported cases in early 2022.